Breaking News
Get 45% Off 0
Selloff or market correction? Either way, here's what to do next
See Overvalued Stocks

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

By Zacks Investment ResearchStock MarketsMar 10, 2020 05:50AM ET
www.investing.com/analysis/crispr-therapeutics-ag-crsp-gains-but-lags-market-what-you-should-know-200514915
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
By Zacks Investment Research   |  Mar 10, 2020 05:50AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-1.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DJI
-1.55%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.67, moving +0.84% from the previous trading session. This move lagged the S&P 500's daily gain of 4.94%. Elsewhere, the Dow gained 4.89%, while the tech-heavy Nasdaq added 4.95%.

Coming into today, shares of the company had lost 21.76% in the past month. In that same time, the Medical sector lost 10.63%, while the S&P 500 lost 17.66%.

Investors will be hoping for strength from CRSP as it approaches its next earnings release. The company is expected to report EPS of -$1.09, down 17.2% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.35 million, up 1824.24% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.54 per share and revenue of $29.11 million. These totals would mark changes of -488.03% and -89.95%, respectively, from last year.

Any recent changes to analyst estimates for CRSP should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.4% higher. CRSP is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 100, which puts it in the top 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.



CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report

Original post

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
 

Related Articles

Dr. Arnout ter Schure
Is the S&P 500 Road to 6400-6500 in Jeopardy? By Dr. Arnout ter Schure - Mar 04, 2025 3

Using the Elliott Wave Principle (EWP), we have been successfully tracking the most likely path forward for the S&P 500 (SPX) over several months. Although there are many ways...

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email